Lopinavir: Protease Inhibitor for HIV Treatment

What is Lopinavir?

Lopinavir is a potent antiretroviral medication classified as a protease inhibitor. It plays a crucial role in the management of Human Immunodeficiency Virus (HIV) infection, primarily when used in combination with other antiretroviral agents. Lopinavir targets a specific enzyme essential for the HIV replication cycle, thereby preventing the virus from maturing and infecting new cells. It is most commonly recognized in its fixed-dose combination with ritonavir, marketed under the brand name Kaletra, although lopinavir is the active antiretroviral component. Understanding lopinavir's role is key to appreciating the advancements in combination antiretroviral therapy (ART) that have transformed HIV from a fatal diagnosis into a manageable chronic condition.

Generic vs. Brand Names

Lopinavir is the generic name for this active pharmaceutical ingredient. As a standalone drug, it is not typically prescribed. Instead, it is almost always formulated in combination with ritonavir, another protease inhibitor that acts as a pharmacokinetic enhancer. This combination is widely known by its brand name, Kaletra. Other potential brand names or formulations might exist in different regions or specific therapeutic contexts, but Kaletra remains the most recognized. The combination of lopinavir and ritonavir is essential for optimizing the drug's effectiveness and dosing schedule.

Mechanism of Action

Lopinavir exerts its antiviral effect by specifically inhibiting the HIV-1 protease enzyme. This enzyme is vital for the final stages of the HIV replication cycle. HIV produces long polyprotein chains that must be cleaved into smaller, functional proteins by the viral protease to assemble new, infectious virions. Lopinavir acts as a competitive inhibitor, binding to the active site of the HIV-1 protease. By blocking this active site, lopinavir prevents the protease from cleaving the viral polyproteins. This results in the production of immature, non-infectious viral particles that are unable to infect new host cells. This disruption at a critical step in viral maturation significantly reduces viral load in infected individuals.

Molecular Level Interactions

The efficacy of lopinavir stems from its precise molecular structure, designed to mimic the natural substrate of the HIV-1 protease. The drug molecule fits snugly into the enzyme's active site, forming strong interactions that prevent substrate binding and cleavage. Key features of lopinavir's structure, such as its amide bonds and hydrophobic pockets, are complementary to the amino acid residues within the protease active site. Ritonavir, when co-administered, inhibits the cytochrome P450 3A4 (CYP3A4) enzyme, which is responsible for metabolizing lopinavir. By inhibiting CYP3A4, ritonavir 'boosts' the concentration of lopinavir in the bloodstream, allowing for less frequent dosing and ensuring that therapeutic levels are maintained for a sufficient duration to effectively suppress viral replication.

Clinical Uses & Indications

Lopinavir, primarily in its combination with ritonavir (Kaletra), is indicated for the treatment of HIV-1 infection in adults and children. It is a cornerstone of combination antiretroviral therapy (ART), which aims to achieve and maintain viral suppression, restore immune function, and prevent opportunistic infections and HIV-related complications. The FDA-approved uses for lopinavir/ritonavir include:

• Treatment of HIV-1 infection in adult and pediatric patients (birth to 16 years of age) when used in combination with other antiretroviral agents.
• It is typically recommended for individuals who have not been previously treated for HIV (treatment-naive) or for those who are switching from other protease inhibitor-based regimens.

The decision to initiate lopinavir/ritonavir as part of an ART regimen is based on various factors, including the patient's viral load, CD4+ T-cell count, potential drug resistance, comorbidities, and potential drug interactions. It is part of a comprehensive strategy to manage HIV as a chronic condition, improving both the quality of life and longevity for infected individuals.

Dosage & Administration

Lopinavir is almost exclusively administered orally, in combination with ritonavir, as part of a fixed-dose formulation. The typical dosage and administration instructions are as follows:

Common Dosage Forms

• Tablets: The most common form is a film-coated tablet containing lopinavir and ritonavir. Typical adult dosages are often 800 mg of lopinavir and 200 mg of ritonavir, taken twice daily.
• Oral Solution: A liquid formulation is available for pediatric patients or individuals who have difficulty swallowing tablets. This formulation requires careful measurement to ensure accurate dosing.

Administration Guidelines

• Lopinavir/ritonavir can be taken with or without food. However, taking it with food may help reduce gastrointestinal side effects.
• Consistency in timing is important for maintaining therapeutic drug levels. Patients are advised to take the medication at the same time(s) each day.
• For pediatric patients, the dose is calculated based on body weight and age, and the oral solution is typically used.
• It is crucial to adhere strictly to the prescribed dosage and not to miss doses, as this can lead to the development of drug resistance.

Always consult with a healthcare professional for specific dosage recommendations and administration instructions tailored to individual patient needs.

Side Effects & Safety

While lopinavir/ritonavir is an effective treatment for HIV, it can cause a range of side effects, varying in severity. Understanding these potential adverse effects and contraindications is essential for safe and effective use.

Common Side Effects

• Gastrointestinal disturbances: Diarrhea, nausea, vomiting, and abdominal pain are among the most frequently reported side effects.
• Fatigue and weakness: General feelings of tiredness can occur.
• Headache
• Changes in lipid levels: Increased cholesterol and triglyceride levels are common and require monitoring.
• Hyperglycemia: Elevated blood sugar levels can occur, particularly in individuals with pre-existing diabetes or risk factors.

Serious Side Effects

• Hepatotoxicity: Liver enzyme elevations and, in rare cases, severe liver damage can occur. Patients with pre-existing liver disease require careful monitoring.
• Pancreatitis: Inflammation of the pancreas, characterized by severe abdominal pain, nausea, and vomiting, can be a serious complication.
• Lipodystrophy: Changes in body fat distribution, including fat accumulation (lipohypertrophy) and fat loss (lipoatrophy), can occur.
• Immune Reconstitution Inflammatory Syndrome (IRIS): In patients with advanced HIV infection and opportunistic infections at the time of ART initiation, IRIS can occur. This is an inflammatory response to a previously unrecognized or subclinical opportunistic infection, which can paradoxically worsen the patient's clinical status.
• QTc Prolongation: Lopinavir/ritonavir can prolong the QTc interval on an electrocardiogram, which may increase the risk of serious cardiac arrhythmias.

Contraindications

Lopinavir/ritonavir is contraindicated in patients with known hypersensitivity to lopinavir, ritonavir, or any of its excipients. It is also contraindicated with certain other medications due to the risk of serious drug interactions, particularly those that are CYP3A4 substrates with narrow therapeutic indices or that prolong the QTc interval. Specific contraindications include co-administration with:

• Certain statins (e.g., simvastatin, lovastatin)
• Rifampin
• Certain antiarrhythmics (e.g., amiodarone, flecainide, propafenone)
• Certain benzodiazepines (e.g., midazolam, triazolam)
• Ergot derivatives
• St. John's Wort

Patients should inform their healthcare provider of all medications, including over-the-counter drugs and herbal supplements, they are taking.

Drug Interactions

Lopinavir, particularly due to the presence of ritonavir, is known to have significant drug-drug interaction potential. Ritonavir is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme, and to a lesser extent, it can also induce or inhibit other CYP enzymes. This means that lopinavir/ritonavir can affect the metabolism of many other drugs, leading to either increased or decreased plasma concentrations and potential toxicity or loss of efficacy.

Notable Interactions

• CYP3A4 Substrates: Drugs that are metabolized by CYP3A4 can have their levels significantly increased when taken with lopinavir/ritonavir. This includes certain statins, calcium channel blockers, immunosuppressants (e.g., cyclosporine, tacrolimus), and anticonvulsants. As mentioned in contraindications, some are strictly avoided.
• CYP3A4 Inducers: Medications that induce CYP3A4 (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) can decrease lopinavir levels, potentially leading to subtherapeutic concentrations and viral resistance.
• Other Protease Inhibitors and Boosters: While lopinavir is often boosted by ritonavir, combining it with other protease inhibitors or boosters may alter its pharmacokinetic profile and is generally not recommended without specific clinical guidance.
• Drugs that Prolong QTc Interval: Co-administration with other drugs known to prolong the QTc interval (e.g., certain antipsychotics, antiarrhythmics, antibiotics like erythromycin) should be done with extreme caution due to an increased risk of torsades de pointes.
• Metformin: Lopinavir/ritonavir can increase metformin levels, potentially leading to lactic acidosis. Careful monitoring of blood glucose and metformin dosage may be necessary.

It is imperative for patients to provide a complete list of all medications, including over-the-counter drugs and herbal supplements, to their healthcare provider to identify and manage potential drug interactions.

Molecular Properties

Understanding the molecular characteristics of lopinavir is fundamental to comprehending its pharmacological behavior and interactions.

Key Molecular Data

• Molecular Formula: C₃₇H₄₈N₆O₅
• Molecular Weight: Approximately 628.8 g/mol
• SMILES Notation: CC(C)[C@H](NC(=O)[C@H](CC(=O)NC1CCCCC1)C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)C(=O)N

Structure Description

The SMILES string CC(C)[C@H](NC(=O)[C@H](CC(=O)NC1CCCCC1)C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)C(=O)N describes the complex three-dimensional structure of lopinavir. It reveals a molecule rich in chiral centers, amide linkages, and hydrophobic regions, which are crucial for its ability to bind to the active site of the HIV-1 protease. The presence of a piperidine ring (NC1CCCCC1) and phenyl groups (Cc1ccccc1, COc1c(C)cccc1C) contributes to its lipophilicity and binding affinity. The stereochemistry indicated by the '@' symbols is critical for its precise fit within the enzyme's pocket, ensuring potent and selective inhibition. The molecule is designed to interact with specific amino acid residues of the protease, blocking its catalytic activity and thereby preventing viral maturation.

Property	Value
Molecular Formula	C37H48N6O5
Molecular Weight	~628.8 g/mol
Drug Class	Protease Inhibitor
Category	Antiviral

Analyze Lopinavir with MolForge

The detailed molecular structure and properties of lopinavir, as represented by its SMILES notation and complex chemical formula, highlight the intricate design required for effective drug action. Understanding these molecular features is key for researchers seeking to discover new antiviral agents or optimize existing ones. MolForge's AI-powered platform offers advanced tools to explore molecules like lopinavir in unprecedented detail. By leveraging our sophisticated algorithms, you can analyze structure-activity relationships, predict pharmacokinetic properties, identify potential drug interactions, and accelerate your drug discovery pipeline. Dive deeper into the world of molecular discovery and innovation; explore lopinavir and countless other compounds with MolForge's powerful AI tools today. Visit our dashboard to begin your analysis.